NO20082345L - Selektive VPAC2 reseptorpeptidagonister - Google Patents
Selektive VPAC2 reseptorpeptidagonisterInfo
- Publication number
- NO20082345L NO20082345L NO20082345A NO20082345A NO20082345L NO 20082345 L NO20082345 L NO 20082345L NO 20082345 A NO20082345 A NO 20082345A NO 20082345 A NO20082345 A NO 20082345A NO 20082345 L NO20082345 L NO 20082345L
- Authority
- NO
- Norway
- Prior art keywords
- vpac2 receptor
- receptor peptide
- peptide agonists
- selective vpac2
- selective
- Prior art date
Links
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 title abstract 2
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Electric Propulsion And Braking For Vehicles (AREA)
- Conductive Materials (AREA)
- Harvester Elements (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73029105P | 2005-10-26 | 2005-10-26 | |
| US74034205P | 2005-11-29 | 2005-11-29 | |
| US74336406P | 2006-02-28 | 2006-02-28 | |
| PCT/US2006/041550 WO2007050651A1 (en) | 2005-10-26 | 2006-10-24 | Selective vpac2 receptor peptide agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082345L true NO20082345L (no) | 2008-05-23 |
Family
ID=37716005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082345A NO20082345L (no) | 2005-10-26 | 2008-05-23 | Selektive VPAC2 reseptorpeptidagonister |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7582608B2 (enExample) |
| EP (1) | EP1942941A1 (enExample) |
| JP (1) | JP2009519212A (enExample) |
| KR (1) | KR101057284B1 (enExample) |
| CN (1) | CN101296708B (enExample) |
| AU (1) | AU2006306236B2 (enExample) |
| BR (1) | BRPI0617740A2 (enExample) |
| CA (1) | CA2627716A1 (enExample) |
| EA (1) | EA012930B1 (enExample) |
| IL (1) | IL189922A0 (enExample) |
| NO (1) | NO20082345L (enExample) |
| WO (1) | WO2007050651A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10328316A1 (de) | 2003-06-23 | 2005-01-20 | Grünenthal GmbH | Verfahren zur Herstellung von Dimethyl-(3-aryl-buthyl)-aminverbindungen als pharmazeutische Wirkstoffe |
| CA2576755A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| US20090170775A1 (en) * | 2004-10-08 | 2009-07-02 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide compositions |
| US7595294B2 (en) * | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| DE102005052588A1 (de) * | 2005-11-02 | 2007-05-10 | Grünenthal GmbH | Verfahren zur Herstellung substituierter Dimethyl-(3-aryl-butyl)-amin-Verbindungen mittels homogener Katalyse |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| TWI448447B (zh) | 2006-07-24 | 2014-08-11 | Gruenenthal Chemie | 製備（１ｒ，２ｒ）-３-（３-二甲胺基-１-乙基-２-甲基-丙基）-酚之方法 |
| JP2011526303A (ja) | 2008-06-27 | 2011-10-06 | デューク ユニバーシティ | エラスチン様ペプチドを含む治療剤 |
| MX366935B (es) * | 2009-08-14 | 2019-07-31 | Phasebio Pharmaceuticals Inc | Peptidos intestinales vasoactivos modificados. |
| CA2784748A1 (en) * | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| EP3139949B1 (en) | 2014-05-08 | 2020-07-29 | Phasebio Pharmaceuticals, Inc. | Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis |
| WO2016130518A2 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
| CN115298194A (zh) * | 2020-03-30 | 2022-11-04 | 一丸自然美健有限公司 | Vipr2拮抗肽 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04193896A (ja) * | 1989-10-26 | 1992-07-13 | Meiji Seika Kaisha Ltd | 活性ペプチド |
| JPH0692991A (ja) * | 1991-02-28 | 1994-04-05 | Daicel Chem Ind Ltd | 新規活性ペプチド |
| WO1998002453A2 (en) | 1996-07-15 | 1998-01-22 | Universite Libre De Bruxelles | Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor |
| US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
| JP2002521390A (ja) | 1998-07-20 | 2002-07-16 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｐａｃａｐのペプチド類似体 |
| US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| WO2000066629A1 (en) | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| PE20010612A1 (es) | 1999-09-28 | 2001-07-12 | Bayer Corp | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico |
| BR0306706A (pt) | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| RU2360922C2 (ru) * | 2002-07-12 | 2009-07-10 | БАЙЕР ХелсКер ЛЛСи | Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения |
| BRPI0407936A (pt) * | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| ATE461217T1 (de) * | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
| KR20070009554A (ko) | 2004-01-27 | 2007-01-18 | 바이엘 파마슈티칼스 코포레이션 | 뇌하수체 아데닐레이트 사이클라제 활성화 펩티드(ｐａｃａｐ) 수용체 (ｖｐａｃ２) 작용제 및 이의약리학적 사용 방법 |
| EP1756156B1 (en) * | 2004-05-21 | 2008-10-22 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA2567635A1 (en) * | 2004-05-21 | 2005-12-01 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA2576755A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| JP2008515437A (ja) | 2004-10-08 | 2008-05-15 | フォーブス メディ−テック（リサーチ） インコーポレーテッド | 血管活性腸管ポリペプチド医薬品 |
| US7595294B2 (en) | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
-
2006
- 2006-10-24 BR BRPI0617740-9A patent/BRPI0617740A2/pt not_active IP Right Cessation
- 2006-10-24 KR KR1020087010055A patent/KR101057284B1/ko not_active Expired - Fee Related
- 2006-10-24 CN CN2006800398953A patent/CN101296708B/zh not_active Expired - Fee Related
- 2006-10-24 EA EA200801180A patent/EA012930B1/ru not_active IP Right Cessation
- 2006-10-24 JP JP2008537892A patent/JP2009519212A/ja active Pending
- 2006-10-24 WO PCT/US2006/041550 patent/WO2007050651A1/en not_active Ceased
- 2006-10-24 EP EP06817361A patent/EP1942941A1/en not_active Withdrawn
- 2006-10-24 US US12/090,656 patent/US7582608B2/en not_active Expired - Fee Related
- 2006-10-24 AU AU2006306236A patent/AU2006306236B2/en not_active Expired - Fee Related
- 2006-10-24 CA CA002627716A patent/CA2627716A1/en not_active Abandoned
-
2008
- 2008-03-04 IL IL189922A patent/IL189922A0/en unknown
- 2008-05-23 NO NO20082345A patent/NO20082345L/no not_active Application Discontinuation
-
2009
- 2009-07-24 US US12/508,584 patent/US7897573B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080234198A1 (en) | 2008-09-25 |
| US7897573B2 (en) | 2011-03-01 |
| KR20080053393A (ko) | 2008-06-12 |
| IL189922A0 (en) | 2008-08-07 |
| US7582608B2 (en) | 2009-09-01 |
| EA012930B1 (ru) | 2010-02-26 |
| AU2006306236B2 (en) | 2011-12-01 |
| EP1942941A1 (en) | 2008-07-16 |
| CN101296708B (zh) | 2011-12-07 |
| CN101296708A (zh) | 2008-10-29 |
| BRPI0617740A2 (pt) | 2011-08-02 |
| WO2007050651A1 (en) | 2007-05-03 |
| EA200801180A1 (ru) | 2008-08-29 |
| CA2627716A1 (en) | 2007-05-03 |
| JP2009519212A (ja) | 2009-05-14 |
| AU2006306236A1 (en) | 2007-05-03 |
| US20100009916A1 (en) | 2010-01-14 |
| KR101057284B1 (ko) | 2011-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082345L (no) | Selektive VPAC2 reseptorpeptidagonister | |
| DOP2006000025A (es) | Agonistas de pyy y sus usos | |
| WO2006097536A3 (en) | Dimeric peptide agonists of the glp-1 receptor | |
| EA200701918A1 (ru) | Белок липокалин | |
| GB0700909D0 (en) | Novel antigen-binding polypeptides and their uses | |
| CY1115004T1 (el) | Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ | |
| MXPA06003474A (es) | Agonistas de receptores de melanocortina. | |
| ATE529442T1 (de) | Verbesserte humane interferon-moleküle und ihre verwendungen | |
| DK2068909T3 (da) | Modificerede FGF-21-polypeptider og anvendelse heraf | |
| DK1692158T3 (da) | VEGF-binding og understøttede peptider til behandling af hudsygdomme | |
| EA201290557A1 (ru) | Пептидный аналог оксинтомодулина | |
| EA200600055A1 (ru) | Агонисты рецептора меланокортина 4 (мк4 ) и их применение | |
| DK3530673T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| MX2009010148A (es) | Peptidos ciclicos de proteinas receptor-asociadas (rap). | |
| EA201071126A1 (ru) | Антагонисты рецепторов глюкагона | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| CY1110980T1 (el) | Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες | |
| WO2007101146A3 (en) | Selective vpac2 receptor peptide agonists | |
| WO2007133828A3 (en) | Selective vpac2 receptor peptide agonists | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| ATE389670T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
| CY1114618T1 (el) | Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη | |
| WO2006023356A3 (en) | Selective vpac2 receptor peptide agonists | |
| EA200702193A1 (ru) | Гликозилирование белков |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |